RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date